Hims & Hers Health (NYSE:HIMS) Posts Earnings Results

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings results on Monday. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03, Briefing.com reports. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. During the same period last year, the business earned ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Hims & Hers Health updated its FY 2024 guidance to EPS and its Q2 2024 guidance to EPS.

Hims & Hers Health Trading Up 5.2 %

Shares of Hims & Hers Health stock traded up $0.63 during trading on Thursday, reaching $12.78. The company’s stock had a trading volume of 3,827,876 shares, compared to its average volume of 5,143,353. The company has a 50-day moving average price of $13.99 and a two-hundred day moving average price of $10.41. The firm has a market cap of $2.74 billion, a PE ratio of -110.55 and a beta of 0.97. Hims & Hers Health has a fifty-two week low of $5.65 and a fifty-two week high of $17.16.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HIMS. Citigroup lifted their price target on shares of Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Tuesday. SVB Leerink assumed coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $10.00 price target for the company. Guggenheim lifted their price target on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Piper Sandler boosted their price objective on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.07.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 97,208 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at approximately $494,835.74. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the transaction, the insider now directly owns 154,345 shares in the company, valued at approximately $1,548,080.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Andrew Dudum sold 97,208 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the transaction, the chief executive officer now owns 51,653 shares in the company, valued at $494,835.74. The disclosure for this sale can be found here. In the last three months, insiders have sold 736,191 shares of company stock valued at $9,733,700. 31.63% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.